1. Welcome to kiwibox

    We're happy that you are part of our community. Please take a few minutes discover how kiwibox works.

    You want to explore kiwibox on your own? No problem. You can easily restart the tour at any time by using the sidebar if you change your mind.

  2. Logo

    A click on the kiwibox Logo brings you back to the startpage. Besides a menue with a lot of useful links opens if you mouse over.

  3. Notifications

    You may find all of your news, friendship requests and messages up right in the navigation bar.

  4. Settings

    Just mouse over a post and the gearwheel will appear. Here you'll find all the settings for your news.

  5. Supermodul

    The supermodul summarizes various contents. Enjoy exploring!

freemanxfyx

freemanxfyx   , 24

from West New York

Statistics

Law Suit Filed: Yasmin and Yaz

Home Page >> Hot Legal Issues >> Lawsuit: Yasmin and Yaz Yasmin/Yaz Birth Control Side Effects Were you looking for Drospirenone lawsuits? Yasmin birth control and Yaz birth control pills have been associated with serious Yaz and Yasmin side effects, including Yasmin blood clots, Yaz blood clots and Yasmin DVT. Ocella side effects have also been reported. Yasmin lawyers are currently investigating possible Yaz and Yasmin settlements with Bayer, the manufacturer. En Espal [ YAZ Y YASMIN ANTICONCEPTIVOS ] FREE CASE EVALUATION Send your Yasmin Birth Control claim to a Lawyer who will review your claim at NO COST or obligation. or call 800-537-1584 Yasmin/Yaz Birth Control Side Effects As of March 2012, approximately 12,000 lawsuits have been brought against Bayer HealthCare Pharmaceuticals, Inc., the manufacturer of Yasmin, Yaz, Beyaz and Safyral, alleging an increased risk of blood clots (deep vein thrombosis (DVT), pulmonary embolism (PE)) and gallbladder problems. Ocella, the generic version of Yasmin, is also associated with serious side effects. As well as blood clots, DVT and pulmonary embolism, all of the oral contraceptives containing ethinyl estradiol and the new "fourth generation" progestin drospirenone (DRSP) have been linked to: Blood Clots Death Yaz and Yasmin Lawsuits: DVT, Blood Clots, PE As of February 1st, 2012, about 12,000 lawsuits are pending in the US against Bayer, on behalf of people who have suffered personal injuries, some fatal, as a result using Yasmin and/or Yaz. Thousands of lawsuits have also been brought against Bayer claiming the fourth generation birth control pills have caused gallbladder problems. At issue is drospirenone, a new synthetic type of progestin that is used in the oral contraceptives in combination with estrogen The lawsuits allege that Bayer failed to adequately warn patients and physicians of the increased risk of serious side effects associated with the use of Yasminand Yaz compared to safer oral contraceptives. Most lawsuits filed to date against the maker of Yaz have been consolidated into a Federal Multi-District Litigation (MDL) court in Illinois, so that each case can be examined separately. They have been consolidated under the case Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100). The first trials were set to begin last fall, 2011, but litigation was postponed indefinitely and both parties were urged by Judge Herndon in Illinois to attempt settlement of the cases. As of February 2012, Bayer announced it has reached an agreement to settle about 70 DVT and pulmonary embolism lawsuits (according to Bayer?s annual report ). To date Bayer has not admitted liability. (Attorneys believe that an MDL, rather than a class action lawsuit, will likely be more successful for those victims who have suffered substantial injuries.) Although personal injury attorneys nationwide are working on settling Yasmin/Yaz DVT and pulmonary embolism lawsuits (gallbladder lawsuits will be reviewed after the initial DVT/pulmonary embolism lawsuits, according to some Yasmin/Yaz attorneys), victims who have not yet filed a claim still have the right to seek compensation. Personal injury attorneys are still filing claims for women potentially injured as a result of taking birth control pills containing drospirenone and ethinylestradiol, particularly Yasmin, Yaz and Ocella. Yasmin FDA Approval & Yaz Problems The US Food and Drug Administration (FDA) approved Yasmin in 2001 for both birth control and treatment of PMDD (Premenstrual Dysphoric Disorder). Yasmin and Yaz were also marketed and prescribed to treat moderate acne. The?miracle drug? Yaz was the top-selling birth control pill in the US in 2008 and 2009, as it was marketed to treat women desperate for severe PMS and acne help. But independent studies involving a million women found that Yaz carries higher blood clotting risks than other leading birth control pills, leading to new scrutiny from safety regulators. Bayer denied wrongdoing. However, Bayer, the maker of the Yasmin contraceptive pill, has been reprimanded on several occasions because of questionable advertising campaigns--the ads were considered misleading in their promise to reduce or cure acne and help with PMS symptoms. Yasmin & Yaz DVT Blood Clot Symptoms Yaz or Yasmin DVT (blood clot) symptoms should be brought to the attention of your medical provider immediately. Symptoms of a Yaz/Yasmin blood clot could include: sudden severe headaches unusual swelling or pain in the legs or arms sharp or crushing chest pain or coughing blood eye problems such as blurred or double vision or complete loss of vision pain in the back of the lower leg Yaz & Yasmin Gallbladder Symptoms In addition to concerns about Yasmin/Yaz blood clots, pulmonary embolism and deep vein thrombosis, Yasmin and Yaz birth control have reportedly been linked to an increased risk of gall bladder problems. The gallbladder aids in the digestive process and concentrates bile produced in the liver. Because Yasmin/Yaz is a diuretic, this oral contraceptive can cause serious gall bladder problems and gallbladder disease that could potentially require surgery for gallbladder removal. Symptoms of Yaz or Yasmin gallbladder problems also require medical attention, as these symptoms may indicate the need for gall bladder surgery or removal. Yaz/Yasmin gallbladder symptoms could include: Pain or discomfort in the upper right side of the abdomen Nausea Jaundice Safyral, Beyaz, Gianvi, Loryna, Ocella, Syeda, Zarah Bayer?s Safyral, a new oral contraceptive, was approved by the FDA in December 2010. This birth control pill (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets) is designed to raise folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a Personal Injury Directory pregnancy conceived while taking Safyral or shortly after discontinuing it. Like Yaz and Yasmin (also made by Bayer), Safyral contains drospirenone, known to increase too much potassium in some consumers. And like Yaz and Yasmin, Safyral has been associated with an increase the risk of serious conditions including blood clots, stroke, and heart attack. The risk of blood clots is highest during the first year of use. Other oral contraceptive brands containing drospirenone include Beyaz and Safyral. Generic versions of Yaz are marketed by Teva (Gianvi) and Sandoz (Loryna). Yasmin generics include Bayer's Ocella, Sandoz's Syeda and Watson Laboratories' Zarah. Bayer HealthCare Pharmaceuticals has warned that women should not use Safyral if?they have kidney, liver, or adrenal disease because this could cause serious heart and health problems, or if they have or have had blood clots, certain cancers, history of heart attack or stroke, or if they are or may be pregnant. Safyral increases the risk of serious conditions including blood clots, stroke and heart attack. Smoking increases these risks, especially in women over 35. The risk of blood clots is highest during the first year of use.? Conflicting Birth Control Studies A number of studies have reached differing conclusions on the risks of newer birth control pills. One study published in the British Medical Journal October 2011 involving more than 1 million Danish women found that women taking Yaz and other newer medications had twice the risk of blood clots as women taking the older hormone levonorgestrel. In 2007, however, two studies published as part of the post-marketing requirements of the FDA or European regulators did not find any difference in blood clotting between the two comparable groups. A recent Yasmin FDA-funded study has shown that preliminary results suggest about a 1.5-fold increase in the risk of blood clots for women who use drospirenone-containing birth control pills compared to users of other hormonal contraceptives. The FDA said it hasn't reached a final conclusion on the drugs' safety; instead an advisory committee meeting was held, to discuss the risks and benefits of birth control pills that contain drospirenone. Here is the complete FDA study. FDA Advisory Panel Conflict of Interest In March 2012, The Washington Monthly and the British Medical Journal (BMJ) reported the FDA advisory panel that voted 15-11 to keep Yaz, Yasmin and other drospirenone birth control drugs on the US market may have a conflict of interest. Four of the FDA panel members that voted in favor of keeping the drugs on the market had a connection with Bayer. Consumer advocacy groups, such as the Project on Government Oversight (POGO), are asking the FDA to re-open the issue about Yaz and Yasmin health risks and remove the four members from the panel. Yaz, Yasmin and related drospirenone-containing pills were Bayer's second-best-selling franchise in 2010 at $1.6 billion in global sales, according to the Associated Press. Yasmin and Yaz Time Line 2001: Yasmin birth control is approved by the FDA. 2002: European regulators express concern about link between Yasmin and venous thrombosis after death of 17-year-old. Dutch doctors are advised not to prescribe Yasmin until studies have established its safety. 2003: Maker of Yasmin is warned by the FDA to stop running misleading advertisements regarding Yasmin. The ads allegedly overstate the product's efficacy while understating the health risks. 2006: Yaz birth control is approved by the FDA. 2009: Bayer is forced by the FDA to run ads clearing up alleged misstatements in advertising for Yaz. The FDA alleges that the Yaz ads overstate the drug's ability to cure acne and treat premenstrual syndrome while downplaying the drug's risks. Lawsuits are filed in the US against Bayer alleging Yaz and Yasmin are associated with an increased risk of Yaz and Yasmin blood clots, heart attack and strokes. 2010: Lawsuits are filed in Canada alleging Yasmin and Yaz are associated with an increased risk of heart attack and strokes. On March 10, 2010, a Canada class action is filed against Bayer in Canada. The certification hearing is scheduled to begin Jan. 28, 2013. September 2011: Yaz bellwether trials get under way. The first Yaz bellwether trial is scheduled to take place September 12, 2011 for pulmonary embolism side effects; that is to be followed by one set for January 9, 2012 and finally a Yaz thromboembolic case on April 2, 2012. October, 2011: The FDA releases a study of more than 800,000 women taking oral contraceptives which shows that those taking drugs like Yaz had a 75 percent increased risk of developing blood clots November 2011: Health Canada announces that a review of drospirenone-containing contraceptives finds 1.5 to 3.0 times the risk of blood clots (Yaz and Yasmin contain drospirenone). The Canadian health agency says that labels have been strengthened to include a warning about the Yaz/Yasmin blood clot risk. The agency further recommends that health care professionals weigh the risks and benefits of certain birth control products that contain drospirenone when determining which contraceptives to prescribe. December 8, 2011: a joint meeting of the FDA committees ends without recommending to pull Yaz and Yasmin from the market. The FDA votes 21 to 5 that labeling on Yaz and Yasmin is inadequate and should be updated to include information from several studies that suggest a higher risk of Yaz blood clots. The group votes 15 to 11 that Yaz, Yasmin and other birth control drugs containing drospirenone are still beneficial and should remain on the market. Some health professionals believe that the newer (i.e., fourth) generation of birth control pills, including Yaz and Yasmin, are no more effective than safer alternatives, and therefore, due to the potential risk of Yaz DVT or Yaz blood clots, safer alternatives should be prescribed. 2012: U.S. District Judge David Herndon cancels the Yaz trial that had been set for January 9, 2012 and orders mediation instead. Should mediation in good faith fail, a trial will start on April 30, 2012. In a follow-up clarification, Herndon warns that if Bayer and Yaz/Yasmin plaintiffs do not act in good faith, he will start remanding cases back to the districts where they began. March 12, 2012: The FDA is asked to reconsider their December 2011 decision concerning the risks of Yaz blood clots versus the benefits of Yaz, Yasmin, Ocella and similar birth control drugs. Bayer settles 70 Yasmin and/or Yaz pulmonary embolism cases. Yasmin Birth Control Legal Help If you or a loved one has suffered an adverse health event such as a blood clot, from using these products, please click the link below and your complaint will be sent to a Yasmin lawyer who may evaluate your claim at no cost or obligation.
For the original version including any supplementary images or video, visit http://www.lawyersandsettlements.com/lawsuit/yasmin-side-effects-yaz-blood.html?ref=rss